Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- AstraZeneca, Osaka Govt Join Forces on Anti-Allergy Measures
September 3, 2019
- Digital Technologies Hold Key for Japan’s Participation in Global Studies: IQVIA R&D Solutions Head
September 3, 2019
- Astellas Revving Up Digital Transformation Drive, Expands Scope of Data to Derive Values
September 2, 2019
- Daiichi Sankyo’s Pain Drug Tarlige Sweeps Promotion Rankings in June: Impact Track
September 2, 2019
- Kadcyla Filed in Japan for Adjuvant Use in Early Breast Cancer
September 2, 2019
- Osaka Startup Looks to Reposition Polaprezinc/Selenium Combination as NASH Treatment
August 30, 2019
- Xofluza Approved in Taiwan: Shionogi
August 30, 2019
- Hisamitsu Seeks Label Expansion for Fentos Tape
August 30, 2019
- 3 Japan Drug Makers Plow US$65 Million into VC Fund
August 30, 2019
- Eisai to Develop Aussie Firm’s Digital Cognitive Function Self-Assessment Tool in Japan
August 29, 2019
- Nippon Kayaku Skips September Listing for Lilly’s Portrazza
August 29, 2019
- Ono Files BTK inhibitor Tirabrutinib in Japan for Primary CNS Lymphoma
August 29, 2019
- Kyowa Kirin Finally Bags US OK for Parkinson’s Disease Istradefylline
August 29, 2019
- Mitsubishi Tanabe Launches US PIII Study of Continuous SC Liquid Levodopa/Carbidopa for Parkinson’s Disease
August 29, 2019
- Towa, Kyoto iPS Upstart Eye Repositioning of Generic Drug for Alzheimer’s
August 27, 2019
- Amicus Raises Its Hands for Sly Syndrome Drug Development in Japan
August 27, 2019
- Kyowa Kirin Starts Japan PIII of Lumicef for Palmoplantar Pustulosis
August 27, 2019
- Nasonex Authorized Generic Now Available
August 26, 2019
- Sawai Aims to See “Branded Generics” Account for One-Third of Its Product Lineup in US in 2024
August 26, 2019
- Astellas/Pfizer’s Xtandi Given FDA’s Priority Review for Hormone-Sensitive Prostate Cancer
August 23, 2019
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…